Eligibility

Individuals 6 months and over who are immunosuppressed, as defined in the immunosuppression rows of Tables 3 or 4 in COVID-19 Greenbook chapter 14a (publishing.service.gov.uk)

For those aged 16 years and over:

Immunosuppression due to disease or treatment, including patients:

• undergoing chemotherapy leading to immunosuppression, patients
• undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).
• Individuals who are receiving immunosuppressive or immunomodulating
• biological therapy including, but not limited to, anti-TNF, elemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.
• Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.
• Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma.
• Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.

For those aged UNDER 16 years:

Immunosuppression due to disease or treatment, including:
• those undergoing chemotherapy or radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients
• genetic disorders affecting the immune system (e.g. deficiencies of IRAK-4 or NEMO, complement disorder, SCID)
• those with haematological malignancy, including leukaemia and lymphoma
• those receiving immunosuppressive or immunomodulating biological therapy
• those treated with or likely to be treated with high or moderate dose corticosteroids
• those receiving any dose of non-biological oral immune modulating drugs e.g. methotrexate, azathioprine, 6-mercaptopurine or mycophenolate
• those with auto-immune diseases who may require long term immunosuppressive treatments

Children who are about to receive planned immunosuppressive therapy should be considered for vaccination prior to commencing therapy.